- Home
- SCYX vs YSXT Comparison
SCYX vs YSXT Comparison
Compare SCYX & YSXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SCYX | YSXT |
|---|---|---|
| Founded | 1999 | 2011 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Automotive Aftermarket |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.3M | 29.5M |
| IPO Year | 2014 | 2024 |
Fundamental Metrics
Financial Performance| Metric | SCYX | YSXT |
|---|---|---|
| Price | $0.77 | $1.13 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | 509.2K | ★ 694.5K |
| Earning Date | 03-11-2026 | 02-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.18 |
| Revenue | $2,932,000.00 | ★ $71,452,736.00 |
| Revenue This Year | $170.77 | N/A |
| Revenue Next Year | $286.38 | N/A |
| P/E Ratio | ★ N/A | $6.52 |
| Revenue Growth | N/A | ★ 22.04 |
| 52 Week Low | $0.57 | $1.07 |
| 52 Week High | $1.31 | $9.96 |
Technical Indicators
Market Signals| Indicator | SCYX | YSXT |
|---|---|---|
| Relative Strength Index (RSI) | 65.55 | 31.49 |
| Support Level | $0.77 | $1.07 |
| Resistance Level | $0.87 | $1.44 |
| Average True Range (ATR) | 0.05 | 0.09 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 61.51 | 16.25 |
Price Performance
Historical ComparisonAbout SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
About YSXT YSX Tech. Co. Ltd Class A Ordinary Shares
YSX Tech Co Ltd provide business solutions to enterprise customers, mainly insurance companies and brokerages, in China. The company has three operating segments: Auto Insurance Aftermarket Value-added Services, Other Scenario-based Customized Services and Software Development and Information Technology Services. Key revenue is generated from Auto Insurance Aftermarket Value-added Services segment which include four types value added services: vehicle safety inspection and check services, vehicle driving risk screening services, designated driver and rescue services and vehicle maintenance and other value-added services.